These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14531924)

  • 21. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR
    Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive deficit in sickle cell disease: Is hydroxyurea part of the story?
    Hyacinth HI; Idris IM
    Br J Haematol; 2020 Jun; 189(6):1014-1015. PubMed ID: 32096223
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia.
    Rankine-Mullings A; Keenan R; Chakravorty S; Inusa B; Telfer P; Velangi M; Ware RE; Moss JJ; Lloyd AL; Edwards S; Mulla H
    Blood Adv; 2023 Aug; 7(16):4319-4322. PubMed ID: 37171600
    [No Abstract]   [Full Text] [Related]  

  • 24. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
    Brawley OW; Cornelius LJ; Edwards LR; Gamble VN; Green BL; Inturrisi C; James AH; Laraque D; Mendez M; Montoya CJ; Pollock BH; Robinson L; Scholnik AP; Schori M
    Ann Intern Med; 2008 Jun; 148(12):932-8. PubMed ID: 18458271
    [No Abstract]   [Full Text] [Related]  

  • 25. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydroxurea and sickle cell disease: Its been a long, long time coming.
    Scott JP
    Pediatr Blood Cancer; 2010 Feb; 54(2):185-6. PubMed ID: 19908298
    [No Abstract]   [Full Text] [Related]  

  • 27. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
    Okam MM; Esrick EB; Mandell E; Campigotto F; Neuberg DS; Ebert BL
    Blood; 2015 Jun; 125(23):3668-9. PubMed ID: 26045597
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of hydroxyurea in sickle cell disease.
    Halsey C; Roberts IA
    Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
    [No Abstract]   [Full Text] [Related]  

  • 30. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST; Rey K; He J; Flanagan J; Fish BJ; Rogers ZR; Wang WC; Ware RE;
    Pediatr Blood Cancer; 2012 Jul; 59(1):170-2. PubMed ID: 21744485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
    Chaine B; Neonato MG; Girot R; Aractingi S
    Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of Seminal Fluid Parameters and Fertility of Male Sickle Cell Disease Patients and Potential Impact of Hydroxyurea Treatment.
    Sahoo LK; Kullu BK; Patel S; Patel NK; Rout P; Purohit P; Meher S
    J Assoc Physicians India; 2017 Jun; 65(6):22-25. PubMed ID: 28782309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
    Rees AL
    J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
    J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
    Rodríguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
    Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.